It is successfully treated with surgery. Gimpy, a coworker of the main character in the 1959 science fiction short story "Flowers for Algernon" by Daniel Keyes, has clubfoot. Kashiwagi, a character in the 1956 novel The Temple of the Golden Pavilion by Yukio Mishima, has clubfoot. It parallels the main character, Mizoguchi, who has a stutter. Johnson, a character in the 1965 short story "The Lame Shall Enter First" by Flannery OConnor, has clubfoot. It is a major symbol in the story. The main character of the 1974 science fiction novel The Bladerunner by Alan E. Nourse has clubfoot. The main character of the 1985 novel Perfume: The Story of a Murderer by Patrick Süskind, has clubfoot. It causes a limp. Senji, a character in the 1987 to 1991 fantasy book series The Mallorean by David Eddings, has clubfoot. Kwai Geuk-Chat, a character in the 1993 film Once Upon a Time in China III, which is part of the 1991 to 1997 Once Upon a Time in China series, has clubfoot. He is nicknamed "Clubfoot Seven Chiu-Tsat" – "Clubfoot" because of his foot, and "Seven Chiu-Tsat" because he is the seventh member of the character Chiu Tin-baks apprentices, disciples, and henchmen. Mordred, King of Dumonia, a character in the 1995 to 1997 historical fantasy book series The Warlord Chronicles by Bernard Cornwell, has clubfoot. It is often used as a symbol for his weakness as a ruler. Charlie Wilcox, the main character of the 2000 childrens book of the same name by Sharon McKay, has clubfoot.
Asparaginase, however, catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine, which leads to cell death. Enzyme regulation
Type I L-asparaginase protein may use the morpheein model of allosteric regulation. Cost
Normal asparaginase costs less than its pegylated version, pegaspargase. However, because it doesnt stay as long in the body, the injections need to be more frequent, with the result that total cost of treatment may be lower for the pegylated version. History
The discovery and development of asparaginase as an anti-cancer drug began in 1953, when scientists first observed that lymphomas in rat and mice regressed after treatment with guinea pig serum. Later it was found out that it is not the serum itself which provoke the tumour regression, but rather the enzyme asparaginase.After researchers comparing different kinds of asparaginases, the one derived from Escherichia coli and Erwinia chrysanthemi turned out to have the best anti-cancer ability. E. coli has thereby become the main source of asparaginase due to the factor that it is also easy to produce in large amount. Society and culture
Names
Crisantaspase is the British Approved Name (BAN) for asparaginase obtained from Erwinia chrysanthemi. Colaspase is the BAN of asparaginase obtained from Escherichia coli. The United States Adopted Name of crisantaspase is asparaginase Erwinia chrysanthemi. Elspar, Kidrolase, Leunase and Spectrila are brand names for colaspase, while Erwinase and Erwinaze are brand names for crisantaspase. The pegylated version of colaspase is called pegaspargase. Oncaspar is the brand name of pegaspargase.